Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 November, 2014 21:23 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*


Related Articles
Essar Steel commissions 6 mtpa pellet complex in Odisha - 27-Nov-2014 18:08
Bank of Baroda plans to raise Rs 15 bn from bonds - 27-Nov-2014 15:14
MMV collaborates with Cipla and Strides - 27-Nov-2014 15:08
MMV collaborates with Cipla and Strides - 27-Nov-2014 15:08
Bharti's Nigeria tower sale is credit positive: Moody's - 27-Nov-2014 15:00
Surana Telecom receives letter of award for solar power project - 27-Nov-2014 14:38
Alstom T&D bags order worth Rs 560 mn - 27-Nov-2014 14:17
Religare retains Sell on Siemens citing high valuations - 27-Nov-2014 12:12
Subex allots shares following bond conversion - 27-Nov-2014 11:13
HDFC Bank allots shares under ESOS - 27-Nov-2014 10:50
8K Miles acquires SERJ solutions to enhance healthcare cloud offering - 27-Nov-2014 10:31
more...
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer